Neurogene (NGNE) Research & Development (2013 - 2026)

Neurogene has reported Research & Development for 14 years, with the latest figure at $25.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 41.61% year-over-year to $25.2 million; the trailing twelve-month figure through Mar 2026 stood at $82.4 million (up 26.5% YoY), and the FY2025 full-year result was $75.0 million, up 23.14% from the prior year.
• Research & Development for Q1 2026 stood at $25.2 million, up from $20.6 million in the prior quarter.
• The five-year high for Research & Development was $25.2 million in Q1 2026, with the low at $9.5 million in Q3 2022.
• Historically, Research & Development has averaged $14.9 million across 5 years, with a median of $15.3 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development jumped 67.8% — and 2023, when it dropped 25.6%.
• Neurogene's Research & Development stood at $16.4 million in 2022, then dropped by 25.6% to $12.2 million in 2023, then grew by 25.96% to $15.3 million in 2024, then jumped by 34.48% to $20.6 million in 2025, then increased by 21.86% to $25.2 million in 2026.
• The last three Research & Development figures came in at $25.2 million (Q1 2026), $20.6 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.